FDA Fast-Tracks Alzheimer’s Drug Lecanemab; Decision Expected By Early 2023
By
Simon Spichak, MSc
| July 7th, 2022
Biogen and Eisai’s next disease-modifying Alzheimer’s drug candidate, lecanemab, has been granted FDA priority review, signaling that a decision could be made by early…
